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sive disease resulting from damage to 
the intestinal mucosa. Dysentery is 
always considered to be severe TD. 
The distinction between intermediate 
and severe TD has limited relevance; 
any degree of incapacitation can be 
troublesome. For example, if a patient 
must miss a business meeting, an 
excursion to an important tourist 
site, or a flight due to TD, then the 
episode is incapacitating, regardless 
of the number of unformed stools or 
accompanying symptoms. 
Without treatment, the average 
episode of TD lasts approximately 
4 days.2,4,5 In approximately half of 
new definitions focus on the func-
tional impact.3 A mild manifestation 
of TD is tolerable, is not distressing, 
and does not interfere with planned 
activities. An intermediate episode 
is distressing and interferes with the 
patient’s plans and ability to function, 
regardless of the number of stools. The 
patient often has substantial accom-
panying symptoms. Severe TD leaves 
the patient completely incapacitated 
and unable to take part in planned 
activities. In general, the patient must 
remain close to a toilet. The presence 
of fever or gross blood mixed in the 
stool can indicate dysentery,2 an inva-
Abstract: The incidence of travelers’ diarrhea (TD) has slightly decreased due to improvements in the hygienic 
conditions seen in many destination countries. However, high-risk areas are still widespread. Previous classification 
based severity on the number of unformed stools passed in 24 hours. Now, TD is differentiated as mild, intermedi-
ate, and severe, with the new definitions focusing on the functional impact. Incapacitation is frequent and can 
result in the need to change travel plans, including cancellation of flights, which results in considerable expense. 
Guidelines published in 2017 offer detailed recommendations for the prophylaxis and management of TD. For 
mild TD, antibiotics are no longer recommended. However, antibiotics provide the most rapid symptom relief for 
patients with intermediate or severe TD, particularly when used in combination with antimotility agents. Fluoro-
quinolones are no longer the first-line antimicrobials against TD because of widespread resistance and evidence 
for the increased risk of multidrug-resistant organisms. Also, side effects are of concern. In November 2018, the 
US Food and Drug Administration approved a new, virtually nonabsorbed antibiotic, rifamycin, for the treatment 
of TD, based on data showing efficacy without evidence of an increase in multidrug resistance. 
Introduction
Travelers’ diarrhea (TD) is the most 
frequent health problem abroad.1 TD 
refers to watery or soft stools that 
are accompanied by symptoms such 
as fecal urgency, abdominal cramps, 
nausea, vomiting, or fever. Each 
year, approximately 15 to 20 million 
people develop TD.2 Previous def-
initions have based severity on the 
number of unformed stools passed in 
24 hours.3
Now, TD is differentiated as mild, 
intermediate, and severe, depending 
on the degree of incapacitation; the 
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patients, symptoms resolve within 48 
hours. Some people experience a spon-
taneous cure after a few hours, but in 
other cases, TD can persist for 2 weeks 
or even longer, particularly in patients 
with an underlying disease.6 
Epidemiology
The incidence of TD has slightly 
decreased due to improvements in the 
hygienic conditions seen in many des-
tination countries in the past decades.7 
During the period just after World 
War II, even southern Europe had a 
fairly high incidence of TD. The inci-
dence has drastically decreased in this 
area,8 as well as in countries in which 
average income rose from low or even 
intermediate levels. For example, the 
incidence rates of TD have decreased 
in China and other countries in 
East Asia, and also in large parts of 
South America.7 In these areas, the 
incidence rates are at an intermediate 
level, which means that 8% to 20% 
of visitors will develop TD during 
the first 2 weeks of their stay. Desti-
nations with high incidence rates, in 
which more than 20% of visitors will 
develop TD, include large portions of 
Central America, as well as countries 
in South Asia, such as India, Pakistan, 
Bangladesh, and Nepal. Other high-
risk destinations include some areas 
in the Middle East and nearly all of 
Africa (with the exception of South 
Africa). Tourist resorts, even in these 
areas, are increasingly taking great 
care to reduce the risk of TD among 
their guests, with some success.
Risk Factors
Risk factors for TD are related to the 
environment and the host (Table 1).9 
Environmental risk factors include the 
macro-epidemiology, meaning a spe-
cific country or region, as well as the 
micro-epidemiology, such as hotels. 
Table 1. Factors Associated With Increased Risk of Acquiring Travelers’ Diarrhea
Factors Mechanism Predictable Pathogens
Adventure travel, 
visiting friends and 
relatives
Varying exposure to contaminated food and beverages All that cause travelers’ diarrhea4
Younger age Unknown; possibly more pathogens ingested (crawling infants, 
larger appetite in adolescents)
All that cause travelers’ diarrhea4
Lack of caution in 
beverage and food 
selection
Varying exposure to contaminated food and beverages All that cause travelers’ diarrhea4
Use of proton pump 
inhibitor therapy
Altered killing of enteric pathogens from gastric hydrochloric 
acid
All bacterial, some parasitic (studies only in 
nontravelers)61
Interleukin 8 AA: high producers leading to greater intestinal 
inflammation
SNP increases frequency of enteroaggregative 
Escherichia coli and Clostridium difficile62,63
Lactoferrin: high producers leading to greater intestinal 
inflammation
SNP increases frequency of all that cause 
travelers’ diarrhea and travelers’ diarrhea with 
intestinal inflammation64
High producers of interleukin 10 are more susceptible to 
travelers’ diarrhea, which may reflect immunomodulatory 
effects of heat-labile toxin of enterotoxigenic E coli, stimulating 
increases in interleukin 10
SNP increases frequency of enterotoxigenic  
E coli travelers’ diarrhea65
Certain genetic 
factors (mostly 
polymorphism 
associations)
Osteoprotegerin: immunoregulatory member of tumor 
necrosis factor receptor superfamily that may function as an 
anti-inflammatory modulator that increases susceptibility to 
travelers’ diarrhea
Especially inflammatory forms of all that cause 
travelers’ diarrhea66
CD14: receptor for bacterial lipopolysaccharide binding associ-
ated with the innate immune response to enteric infection and 
inflammation; different SNPs may increase susceptibility to 
travelers’ diarrhea; others may lead to protection
SNPs leading to high production are associated 
with travelers’ diarrhea67
Type O blood may influence enteric infection through 
uncertain mechanisms
Cholera and severe cholera caused by
Vibrio cholerae O168
Not possessing the nonsense mutation in the FUT2 gene that 
provides resistance to infection related to virus attachment and 
internalization
Noroviruses69
SNP, single-nucleotide polymorphism.
Data from Steffen R et al. JAMA. 2015;313(1):71-80.9
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According to a survey on the incidence 
of TD at hotels in Jamaica with at least 
40 clients,10 one hotel had zero cases, 
a few had an incidence of less than 
10%, and some exceeded 30%. The 
incidence of TD mirrors the hygienic 
conditions in the kitchen.11 TD can 
affect anyone, even guests at 5-star 
hotels.2
Other environmental risk fac-
tors include the characteristics of 
travel. Backpackers who obtain raw 
or improperly cooked food from 
street vendors are at highest risk.7,12-14 
Trips that involve multiple destina-
tions have a higher incidence rate as 
compared with a visit to one loca-
tion. The incidence of TD has been 
shown to be higher in all-inclusive 
trips, most likely because visitors may 
overindulge in unlimited alcoholic 
drinks.14,15 Consumption of alcohol 
can result in diarrhea, even without 
contamination from food and bever-
ages. Mountaineering is also associated 
with a considerable risk of TD. Higher 
rates have been seen among travelers 
to the Mount Everest region in Nepal 
and Denali (formerly known as Mount 
McKinley) in Alaska.7,16-18
There are several host risk fac-
tors. In all studies, the incidence of 
TD is highest among young people, 
ages 15 to 30 years.19-21 The reason 
is unknown, but it may be because 
younger people have a larger appetite 
and therefore ingest more pathogens 
as compared with senior travelers.9,22 
This age-related difference is main-
tained even among groups of travelers 
who stay at the same hotel with all-
inclusive menus. TD is not more fre-
quent in either sex, although women 
may have a stronger perception of the 
disorder and seek care more often.23 
Travelers originating in countries 
with an intermediate or high risk of 
TD have a far lower incidence rate 
compared with those from low-risk 
countries.1,24,25 Also, those who stay 
in a developing country apparently 
develop some immunity, which par-
tially protects them for a few months 
during subsequent travel (Table 2).26 
There may be a genetic predisposi-
tion toward developing the disorder.9 
Preexisting illnesses, such as gastroin-
testinal disorders and possibly immu-
nodeficiency, may result in a high risk 
of TD. Lack of gastric acids has also 
been associated with a high risk.27
Complications and Impact
In the acute phase of TD, the foremost 
complication is dehydration. Patients 
may collapse, particularly when in a 
tropical climate.
Incapacitation is frequent and can 
be troubling. For example, if several 
family members or friends are travel-
ing together, even if only one of them 
develops TD, it can be disruptive for 
the entire group. One or more of the 
healthy travelers may need to stay 
behind to care for the person with TD. 
Cancellation of flights and other travel 
arrangements can result in consider-
able expense.
Longer-Term Complications
Intermediate or long-term compli-
cations include irritable bowel syn-
drome,7,28 as well as acquisition of 
extended-spectrum beta lactamase-
producing Enterobacteriaceae.29 More 
rare complications include reactive 
arthritis, hemolytic-uremic syndrome, 
Guillain-Barré syndrome, and diarrhea 
associated with Clostridium difficile.7,30
Etiology of TD
TD can be caused by bacteria, viruses, 
and parasites (Table 3).3 Bacteria are 
responsible for at least 80% of cases, 
whereas viruses cause approximately 
5% to 10%. These statistics vary 
Table 2. Risk of Travelers’ Diarrhea in a New Destination Among People Who Traveled in the Previous 12 Months
Totala With TD Without TD P Value
n (%) n (%) n (%)
Previous antibiotic use No 133 (77.8) 49 (36.8) 84 (63.2)  0.309 
Yes 38 (22.2) 17 (44.7) 21 (55.3) 
History of TD  No 158 (92.4)  60 (38.0)  98 (62.0)  0.376
Yes 13 (7.6) 7 (53.8) 6 (46.2) 
TD risk at previous destinationb No/low 80 (46.8) 34 (42.5) 46 (57.5) 0.362 
Intermediate 53 (31.0)  21 (39.6) 32 (60.4) 
High 38 (22.2) 11 (28.9)  27 (71.1) 
Same region No 142 (86.1)  51 (36.2)  90 (63.8) 
Yes 23 (13.9)  9 (39.1)  14 (60.9) 
TD, travelers’ diarrhea.
aThere was missing information for some of the variables.
bNo/low: <8% (including participants who have not travelled within the past 12 months); intermediate: 8% to 20%; high: >20% (according to Steffen R et al. 
JAMA. 2015;313(1):71-809).
Data from Kuenzli E et al. J Travel Med. 2017;24(5).26
6  Gastroenterology & Hepatology  Volume 14, Issue 12, Supplement 8  December 2018
R E V I E W  A R T I C L E
according to geographic location. Up 
to 60% of infections have a mixed 
etiology.
Parasites, such as Entamoeba 
histolytica, Giardia lamblia, or Cryp-
tosporidium, are a rare cause of TD,31 
accounting for less than 5%, or even 
less than 2%, of cases, depending on 
the destination. However, TD caused 
by parasites tends to persist after the 
patient returns home. In industrial-
ized countries, the percentage of 
patients with TD caused by a patho-
gen is far higher than 5% because 
these cases tend to last longer and 
require treatment. Most cases caused 
by bacteria or a virus will eventually 
resolve without treatment.32
Prevention
Dietary Methods
The traditional rule for prevention of 
TD was, “Boil it, cook it, peel it, or 
forget it.” There is, however, no evi-
dence that this approach substantially 
reduces the rates of TD.33 There may 
even be higher rates of diarrhea among 
travelers who tried to be careful about 
what they ate, as compared with those 
who claimed to eat anything, includ-
ing salads from buffets or even beef 
tartar and raw oysters.4,15 These stud-
ies, however, have often been biased 
by a retrospective approach. There 
has been only one prospective study, 
which was performed at my clinic.34 
Unfortunately, the answer rate in 
this study was too low to permit any 
conclusions. It is therefore not known 
whether so-called dangerous foods 
should be avoided. Only a small 
proportion of travelers follow the 
advice to eat food that is boiled, 
cooked, or peeled.34 Most travelers 
drink fruit juices, eat salads, and con-
sume food from buffets; often, there 
is nothing else available.15
Medical Prophylaxis
Drug prophylaxis for TD is more 
often recommended and used in the 
United States than elsewhere. In fact, 
European travelers are even reluctant 
to use prophylaxis against malaria. 
Bismuth subsalicylate is an option 
for any traveler for the prevention of 
TD.3 Antibiotic prophylaxis is pre-
scribed in certain circumstances, such 
as patients with a preexisting illness 
of the gastrointestinal tract or those 
likely to develop serious complica-
tions after TD.3 Antimicrobial pro-
phylaxis might also be considered for 
patients attending important func-
tions, who cannot risk being incapaci-
tated for even a few hours. Rifaximin 
is the recommended antibiotic for use 
as prophylaxis.3 Fluoroquinolones are 
no longer recommended.
Treatment
The treatment options for TD vary 
according to the severity of the case. 
Oral rehydration therapy as a support-
ive measure is the treatment of choice 
for infants, children, and the elderly. It 
is necessary to avoid dehydration and 
electrolyte imbalance. Such medica-
tions are available everywhere. In con-
trast, there are advantages to equip-
ping future travelers with a travel kit 
with additional TD medication, since 
in many countries TD patients other-
wise are at risk of counterfeit drugs,35 
obsolete medication, or even unneces-
sary hospitalization by some doctors 
practicing close to tourist resorts.36
Mild
According to 2017 guidelines from 
Riddle and colleagues, mild TD should 
not be treated with antibiotics.3 A mild 
episode can be treated with small doses 
of antimotility agents, such as loper-
amide, or bismuth subsalicylate. (In 
Europe, bismuth subsalicylate is not 
widely available and rarely used.) Acti-
vated charcoal and dimenhydrinate are 
not recommended for TD patients. 
Moderate
In some cases, antibiotics can be used 
to treat patients with moderate TD.3 
Antibiotics, particularly when used in 
combination with antimotility agents, 
provide the most rapid symptom relief 
for patients with TD. Alone, they can 
reduce the average duration to slightly 
longer than a day, or even half a day 
when combined with loperamide.3 
Single-dose antibiotic regimens are 
preferred. Options mainly include 
azithromycin and rifaximin. The 
recently approved rifamycin is also an 
option for moderate TD.37
Until a few years ago, fluoroqui-
nolones were the most commonly used 
class of antibiotics. There is increasing 
reluctance to use fluoroquinolones 
because of increasing resistance, acqui-
sition of multiresistant pathogens, and 
risk of adverse events.3,38,39 There is evi-
dence for the increased risk of multi-
drug-resistant organisms, particularly 
Table 3. Estimated Regional Differences in the Etiology of Travelers’ Diarrheaa
Organism
Reported Pathogens (%)
Latin America 
and Caribbean Africa
South 
Asia
Southeast 
Asia
Enterotoxigenic  
Escherichia coli
≥35 25-35 15-25 5-15
Enteroaggregative E coli 25-35 <5 15-25 No data
Campylobacter <5 <5 15-25 25-35
Salmonella <5 5-15 <5 5-15
Shigella 5-15 5-15 5-15 <5
Norovirus 15-25 15-25 5-15 <5
Rotavirus 15-25 5-15 5-15 <5
Giardia <5 <5 5-15 5-15
aStudies do not uniformly report on all pathogens; no pathogen was identified in up to 50% of cases. 
Data from Steffen R et al. JAMA. 2015;313(1):71-80,9 based on studies conducted in 2002 to 2011.70-75
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with ciprofloxacin. The recent guide-
lines cite an incrementally increasing 
association between travel, TD, and 
use of antibiotics with the acquisition 
of multidrug-resistant bacteria.3 Before 
they leave for a trip, patients should be 
informed about how this risk can be 
balanced against the benefits associated 
with the use of antibiotics.
Another concern with tradi-
tional antibiotics is their side effects. 
Ciprofloxacin in particular has been 
associated with adverse events.40,41
Caution should be exercised when 
using rifaximin as empirical therapy 
for moderate diarrhea in regions 
associated with a high risk of invasive 
pathogens. 
Loperamide can be used as mono-
therapy or adjunctive treatment for 
moderate TD.3 Bismuth subsalicylate 
is another option.
Severe
Patients with severe TD should receive 
treatment with antibiotics, possibly 
combined with loperamide.3 Single-
dose regimens may be used. Azithro-
mycin is the preferred antibiotic. 
Fluoroquinolones or nonabsorbable 
rifaximin may be used to treat severe, 
nondysenteric TD. Similar to the treat-
ment of moderate TD, the recently 
approved rifamycin is an option for the 
treatment of severe TD.37
Currently, the most commonly 
used antibiotics for TD are azithromy-
cin and nonabsorbable rifaximin. Both 
of these treatments are recommended 
by the new guidelines.3 A disadvantage 
to azithromycin is that it may cause 
nausea, particularly if used at a higher 
dosage. Rifaximin and rifamycin are 
nonabsorbable and therefore do not 
cause any such side effects. In patients 
with dysentery, azithromycin is the 
first choice because rifaximin and rifa-
mycin are unlikely to be effective in an 
invasive infection.3 
Rifamycin
The new MMX formulation of rifa-
mycin (Aemcolo, Aries Pharmaceuti-
cals, Inc. [a Cosmo Pharmaceuticals 
N.V. Company]) was approved 
for TD by the US Food and Drug 
Administration in November 2018.42 
Rifamycin is similar to rifaximin, 
an enteric antibiotic that is poorly 
absorbed.43,44 Rifamycin incorporates 
a multimatrix (MMX) technology, 
which delays release of the drug after 
ingestion.45 The drug is released when 
it encounters intestinal pH levels of 
7 or higher.46 Rifamycin is therefore 
active only in the colon and the lower 
part of the ileum. Similarly to rifaxi-
min, as a nonabsorbable antibiotic, 
rifamycin is associated with a low rate 
of adverse events.46 This therapy also 
has anti-inflammatory properties.47
Study Data
An in vitro study by Farrell and col-
leagues showed that rifamycin was 
potent against enteropathogens com-
monly associated with TD.48 Rifamy-
cin was tested for activity against 911 
enteropathogens and 30 C difficile iso-
lates gathered from global surveillance 
studies. Values of minimum inhibitory 
concentration (MIC) were measured. 
Against Enterobacteriaceae strains, 
MIC50 values ranged from 32 µg/mL 
to 128 µg/mL for all but 1 strain (an 
enterotoxigenic Escherichia coli at >512 
µg/mL). Against non-Enterobacteria-
ceae strains, MIC50 values ranged from 
2 µg/mL to 8 µg/mL. (The one excep-
tion was Campylobacter species, which 
had MIC values >512 µg/mL.) 
Rifamycin was very active (MIC50, 
≤0.03 µg/mL) against 26 of 30 strains 
of C difficile (including 1 hypervirulent 
NAP1 strain). Among the 4 remaining 
strains (which also included a hyper-
virulent NAP1 strain), MIC values 
ranged from 256 µg/mL to 512 µg/
mL. Less activity against C difficile 
strains (including a hypervirulent 
NAP1 strain) was observed with 
rifaximin (MIC50, 0.12 µg/mL), met-
ronidazole (MIC50, 0.25 µg/mL), and 
vancomycin (MIC50, 0.5 µg/mL).
In a study of healthy volunteers, 
rifamycin was poorly absorbed after 
oral treatment given in single- and 
multiple-dose regimens.46 The oral 
bioavailability was 0.1%. The amount 
of systemically absorbed drug excreted 
in the urine was less than 0.01% of the 
administered dose (in both the single- 
and multiple-dose regimens). In the 
feces, the administered dose was elimi-
nated at a rate of 87%. The absolute 
bioavailability was 0.0410 ±0.0617 
after a single intravenous injection and 
after a single oral dose under fasting 
conditions (as calculated by the mean 
percent ratio between total urinary 
excretion amounts).
A phase 2 trial of rifamycin vs 
rifaximin confirmed the efficacy and 
safety of the new treatment among 
115 patients with active infectious 
diarrhea.49 Treatment was successful in 
47.8% of the rifamycin arm vs 50.9% 
of the rifaximin arm. The median time 
to last unformed stool (TLUS) was 
67.5 hours with rifamycin vs 65.5 
hours with rifaximin. Isolates of Cam-
pylobacter jejuni, C lari, E coli, Anaero-
biospirillum, Salmonella enteritidis, and 
Shigella flexneri identified at baseline 
were no longer retrievable after treat-
ment with rifamycin.
Adverse events occurred in 29 
patients treated with rifamycin vs 
25 patients treated with rifaximin 
(Table 4). There were similar rates of 
constipation, worsening of diarrhea/
aggravated diarrhea, and development 
of yeasts in feces.
A randomized, double-blind 
phase 3 trial by DuPont and col-
leagues compared rifamycin (2 × 
200 mg twice daily for 3 days) vs 
placebo.50 The primary endpoint was 
TLUS, defined as the interval between 
the first dose of study drug and the 
time the last unformed stool was 
passed. TLUS was 46.0 hours with 
rifamycin vs 68.0 hours with placebo, 
a significant difference (P=.0008). A 
clinical cure was reported in 81.4% 
of the rifamycin arm vs 56.9% of the 
placebo arm (Figure 1). The rates of 
pathogen eradication were 67.0% 
with rifamycin vs 54.8% with pla-
cebo, but this difference did not reach 
statistical significance (P=.0836). 
After treatment with rifamycin, in 
vitro studies showed resistance to 
rifamycin in some remaining bacteria, 
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My colleagues and I performed 
a randomized, double-blind phase 3 
study comparing rifamycin (400 mg 
twice daily) vs ciprofloxacin (500 mg 
twice daily; at the time of study design, 
the first-line drug) for the treatment of 
TD.51 The study was designed to prove 
noninferiority of rifamycin compared 
with ciprofloxacin. The primary end-
point was TLUS, which was defined as 
the interval between the first dose of 
the study drug and the last unformed 
stool passed before the end of the 
clinical cure period. This conservative 
definition of TLUS differs from that 
seen in other trials, which limits the 
duration to before the start of the clini-
cal cure period.
The study randomly assigned 
treatment to 835 international visi-
tors who developed acute TD. Most 
patients were traveling in India 
(n=805), and the others were in Gua-
temala or Ecuador (n=30). Patients 
had experienced at least 3 unformed, 
watery or soft stools within 24 hours 
before randomization, with the illness 
lasting no more than 72 hours. All 
patients also reported at least 1 moder-
ate to severe sign or symptom of enteric 
infection (eg, gas/flatulence, nausea, 
vomiting, abdominal cramps or pain, 
rectal tenesmus, fecal urgency). Exclu-
sion criteria included passage of gross 
bloody stools, known or suspected 
infection with a nonbacterial pathogen 
(eg, human immunodeficiency virus 
or viral hepatitis), moderate or severe 
dehydration, history of inflammatory 
bowel disease or celiac disease, and use 
of more than 2 doses of an antidiar-
rheal medication within 24 hours or 
use of an antibiotic within 7 days prior 
to randomization.
Treatment was completed by 
814 patients (97.5%) in the study, 
and discontinuation rates were simi-
lar in both arms. In the per-protocol 
analysis, the median TLUS was 42.8 
hours with rifamycin vs 36.8 hours 
with ciprofloxacin. This difference 
indicated that rifamycin was noninfe-
rior to ciprofloxacin (P=.0035). The 
intent-to-treat analysis confirmed this 
noninferiority. The median TLUS 
rifamycin arm, the next most common 
adverse events were headache (occurring 
in 8.5%) and constipation (occurring in 
3.5%). There were no reports of amebic 
dysentery or gastrointestinal infection 
among patients treated with rifamycin. 
Each of these adverse events occurred in 
3.1% of patients receiving placebo.
but this finding did not correspond to 
lower efficacy. 
Adverse events occurred in 29.6% 
of the rifamycin arm vs 38.5% of the 
placebo arm. Diarrhea, the most com-
mon adverse event, was reported in 
10.0% of the rifamycin patients and 
16.9% of the placebo patients. In the 
Table 4. Summary of Some Adverse Events That Occurred Throughout a Study of 
Rifamycin vs Rifaximin (Safety Population)
Adverse Event Rifamycin Rifaximin
Headache 14 12
Nausea 3 1
Constipation 4 4
Aggravated diarrhea 3 4
Diarrhea 1 —
Pyrexia 1 1
Dehydration 1 1
Abdominal wind 1 1
Abdominal cramps 1 1
Abdominal pain 1 2
Abdominal spasm — 1
Data from Di Stefano AFD et al. Antiinfect Agents. 2013;11:192-203.49
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patients may have received obsolete 
or inappropriate therapies during 
their travels.36 For the management, 
it is not necessary to learn where the 
patient was traveling, what he or she 
ate, or whether the trip was for busi-
ness or pleasure, but it is always nice to 
express a general interest and empathy 
for the patient’s history. The patient 
may urgently require rehydration and/
or treatment for relief of symptoms. In 
general, patients should not be treated 
with the same medication they already 
received.
Traditional microbiologic testing 
is not needed in uncomplicated cases; 
hopefully, the patient will be cured 
before the results arrive. In contrast, 
testing is recommended in patients 
with severe TD or persistent symptoms 
or when antibiotic therapy was unsuc-
cessful.3 In patients with dysentery, 
there is general agreement that labora-
tory tests are needed. Molecular testing 
for clinically relevant pathogens is 
preferred when rapid results are needed 
Currently, there is no effective 
vaccine against TD. In Canada, the 
oral cholera vaccine originally was rec-
ommended as prophylaxis against TD, 
but since 2015, the indication has been 
limited to TD associated with E coli. 
In the European Union, this vaccine 
is used only to protect against cholera, 
and most experts agree that it has, at 
best, a minimal impact on the TD 
incidence rate59—far less, for example, 
than the influenza vaccine. Several vac-
cine candidates are in the pipeline.60
Evaluation of a Patient After 
a Trip
When a patient returns with TD after 
a trip, it is first necessary to take a 
history and to assess the symptoms, 
particularly the degree of incapacita-
tion. The date of onset is important, 
to determine whether the diarrhea is 
acute, persistent, or chronic. Also, one 
needs to learn what therapy already has 
failed to improve the condition. Some 
was 44.3 hours with rifamycin vs 40.3 
hours with ciprofloxacin (P=.0011). 
There were no statistically significant 
differences between the treatment 
groups for the secondary endpoints of 
clinical cure rate, treatment failure rate, 
and requirement of rescue therapy. A 
subgroup analysis found that earlier 
initiation of either treatment corre-
sponded to a shorter TLUS.
Adverse events occurred in 14.8% 
of the rifamycin arm and 14.9% of 
the ciprofloxacin arm. Adverse drug 
reactions occurred in 8.1% vs 7.5%, 
respectively. There were no reports of 
serious adverse events or deaths. 
As mentioned, multidrug resis-
tance is a concern with ciprofloxacin 
and other fluoroquinolones. An inter-
esting finding in the trial was that 
rifamycin did not increase multidrug 
resistance.51 Among patients in the cip-
rofloxacin arm, colonization rates with 
extended-spectrum beta lactamase– 
producing E coli increased by 6.9% 
after 3 days of treatment (Figure 2). 
In contrast, this rate did not increase 
among patients treated with rifamy-
cin. These data were shown in a study 
presented at the 2017 Digestive Dis-
ease Week and the 15th Conference 
of the International Society of Travel 
Medicine.52,53
Other Emerging Treatments
Studies of the gut microbiome in trav-
elers with and without diarrhea may 
clarify the use of current and novel 
preventive, diagnostic, and therapeutic 
approaches.54 Currently, there is insuf-
ficient evidence to recommend the use 
of commercially available prebiotics or 
probiotics to prevent or treat TD.3,55,56 
However, there is reason to expect 
that next-generation probiotics could 
bolster colonization resistance against 
pathogens and thus prevent TD.57 
Since there is a lack of evidence sup-
porting the use of antisecretory agents, 
such as crofelemer and racecadotril, in 
the setting of TD, these agents are not 
broadly recommended.3 Only zalda-
ride has been evaluated, but this agent 
is not marketed anywhere.58
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or when nonmolecular tests did not 
establish a diagnosis. If the patient pre-
viously received antimicrobial agents 
without any improvement of the con-
dition, then I would obtain a stool test 
for parasites. If the patient has received 
an antimicrobial agent and is very 
incapacitated or even has dysentery, 
then I may consider another antibi-
otic. Despite the lack of evidence, I 
occasionally may use probiotics when 
the symptoms are mild and my inten-
tion is to avoid harm while gaining 
time toward a spontaneous cure. 
Approximately 6% of patients 
have diarrhea that is persistent (lasting 
more than 2 weeks).6 This type of TD 
may be associated with undiagnosed 
parasitic gastrointestinal infection, 
which needs to be treated appropriately. 
The probability of a bacterial infection 
decreases with the duration of symp-
toms. In some cases, the episode of TD 
unmasks a previously undiagnosed gas-
trointestinal disease, such as idiopathic 
inflammatory bowel disease, celiac 
sprue, or lactose intolerance. Initial 
evaluation should include a complete 
blood count to check for anemia and 
eosinophilia, stool analysis (polymerase 
chain reaction is preferred), an assay for 
C difficile, and celiac serologies. Patients 
may exhibit postinfectious sequela of an 
enteric infection. 
Conclusion
Management of TD continues to 
evolve. Guidelines offer detailed rec-
ommendations for the many different 
scenarios that can arise. For the many 
patients with mild TD, antibiotics are 
now contraindicated since they may 
be associated with adverse events and 
resistance. In contrast, these agents 
may or should be used in more severe 
forms of TD. While quinolones have 
lost their position as first-choice anti-
microbials in TD for a number of rea-
sons, the nonabsorbed agents rifaximin 
and the newer treatment rifamycin are 
attractive options for the therapy of 
noninvasive TD. In particular, it has 
been shown that patients receiving 
rifamycin for the treatment of TD 
are not at increased risk of acquiring 
multidrug-resistant pathogens. 
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